OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2021 User Fees

FDA Grand Rounds - Advancing Real World Evidence in FDA Regulatory Decision Making

ANDA Labeling: Helpful Hints and Resources

FDA Grand Rounds - Antibody Glycosylation Insights for High Quality Biotherapeutics

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

Conversations on Cancer – Perspectives on Cancer Care Decision-Making Among Older Adults

OTC Monograph Reform: OTC Sunscreen Drugs

FDA Expert Panel on Food Allergies

FDA Grand Rounds - Adopting Large Language Models for Regulatory Review

FDA Grand Rounds - Postmarket Regulation of Cosmetic Products: The Who, What, When, Why, and How

FDA Direct: Combating Rare Diseases at the FDA

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA Grand Rounds - Statistical Considerations for Drug Development in Rare Disease

FDA Grand Rounds - Anti biofilm Technologies for Enhancing the Safety of Medical Device Surfaces

FDA's Public Meeting on Food Allergen Thresholds - 02/18/2026

FDA Grand Rounds - Forensic Proteomics Applied to FDA Regulated Products

FDA’s Rare Disease Day 2026 – An Event for Patients

Drug Master File (DMF) Submissions on New FDA Form 3938

January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

Roundtable on PMTA Submissions for ENDS Products